Stock Scorecard

Stock Summary for Genfit (GNFT) - $3.44 as of 12/9/2023 10:03:40 AM EST

Total Score

10 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for GNFT

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for GNFT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for GNFT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for GNFT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for GNFT

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis ( PBC ) 12/8/2023 6:55:00 AM
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis ( PBC ) 12/8/2023 6:55:00 AM
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC 12/7/2023 10:15:00 AM
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC - Ipsen ( OTC:IPSEY ) 12/7/2023 6:00:00 AM
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC 12/7/2023 6:00:00 AM
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials 12/6/2023 4:30:00 PM
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials 12/6/2023 4:30:00 PM
GENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023 11/16/2023 9:10:00 PM
GENFIT Highlights ACLF Development Strategy at "ACLF Day" during AASLD The Liver Meeting® 2023 11/16/2023 9:10:00 PM
GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine 11/13/2023 9:30:00 PM

Financial Details for GNFT

Company Overview
Ticker GNFT
Company Name Genfit
Country USA
Description Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company is headquartered in Loos, France.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2023
Next Earnings Date N/A

Stock Price History
Last Day Price 3.44
Last Day Price Updated 12/9/2023 10:03:40 AM EST
Last Day Volume 148,945
Average Daily Volume 17,113
52-Week High 4.75
52-Week Low 2.89
Last Price to 52 Week Low 19.03 %

Valuation Measures
Trailing PE N/A
Industry PE 158.38
Sector PE 62.37
5-Year Average PE 12.49
Free Cash Flow Ratio 1.54
Industry Free Cash Flow Ratio 17.89
Sector Free Cash Flow Ratio 31.15
Current Ratio Most Recent Quarter 2.95
Total Cash Per Share 2.24
Book Value Per Share Most Recent Quarter 1.50
Price to Book Ratio 2.13
Industry Price to Book Ratio 4.65
Sector Price to Book Ratio 19.59
Price to Sales Ratio Twelve Trailing Months 5.86
Industry Price to Sales Ratio Twelve Trailing Months 16.60
Sector Price to Sales Ratio Twelve Trailing Months 5.61

Share Statistics
Total Shares Outstanding 49,835,000
Market Capitalization 171,432,400
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Dividend King? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth -135.27 %
Reported EPS 12 Trailing Months -0.78
Reported EPS Past Year 0.00
Reported EPS Prior Year 0.11
Net Income Twelve Trailing Months 0
Net Income Past Year -23,720,000
Net Income Prior Year 67,259,000
Quarterly Revenue Growth YOY 24.50 %
5-Year Revenue Growth 313.62 %

Balance Sheet
Total Cash Most Recent Quarter 111,826,000
Total Cash Past Year 136,001,000
Total Cash Prior Year 258,756,000
Net Cash Position Most Recent Quarter 49,177,000
Net Cash Position Past Year 65,806,000
Long Term Debt Past Year 70,195,000
Long Term Debt Prior Year 72,047,000
Total Debt Most Recent Quarter 62,649,000
Equity to Debt Ratio Past Year 0.57
Equity to Debt Ratio Most Recent Quarter 0.54
Total Stockholder Equity Past Year 94,528,000
Total Stockholder Equity Prior Year 119,097,000
Total Stockholder Equity Most Recent Quarter 74,520,000

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.02
MACD Signal 0.01
20-Day Bollinger Lower Band 2.91
20-Day Bollinger Middle Band 3.41
20-Day Bollinger Upper Band 3.90
Beta 0.89
RSI 60.08
50-Day SMA 3.87
200-Day SMA 5.08

System
Modified 12/9/2023 10:04:26 AM EST